Skip to content

    How did STEP trial participants describe their physical functioning?

    How did STEP trial participants describe their physical functioning?

    What would make daily life feel easier for you? Maybe it's carrying groceries, walking to the mailbox, standing through a concert, or bending down to tie a shoe. Those experiences can matter just as much as a number on the scale.

    Researchers in several semaglutide studies asked participants about physical functioning as part of their follow-up. Their answers offer a view of treatment that a weight measurement alone can't provide. They also need careful interpretation: a questionnaire result is a group finding, not a promise about a particular activity.

    Why ask participants directly?

    A lab result or a scale can measure something important, but neither can fully describe how a person experiences everyday life. Patient-reported questionnaires give participants a structured way to describe activities, limitations, and aspects of quality of life.

    In the STEP 1–4 trials, researchers used a general health questionnaire that includes physical-function questions. In STEP 1 and STEP 2, they also used a weight-related quality-of-life questionnaire with a physical-function section. Participants completed the measures at planned points in the studies, and researchers compared score changes between groups.

    The questions are designed to capture reported experience. They are not the same as timing someone on a walk, measuring muscle strength, or watching them climb stairs. Both kinds of information can be valuable, but they answer different questions.

    The people and study designs weren't identical

    STEP 1, 3, and 4 included adults with overweight or obesity without type 2 diabetes. STEP 2 included adults with type 2 diabetes and a body mass index of at least 27. The trials compared injectable semaglutide with placebo alongside lifestyle support, but the details of the programs and comparisons differed.

    For example, STEP 3 included a more intensive behavioral program. STEP 4 had an initial period during which participants received semaglutide; eligible participants were then assigned to continue it or switch to placebo. That design asks a different question from assigning treatment at the beginning of the study.

    The STEP trials were sponsored by Novo Nordisk, the manufacturer of semaglutide. That is useful context alongside the trial designs, the full results, and the study limitations.

    What did the questionnaires ask about?

    One physical-function section included questions about experiences such as bending over, standing comfortably, feeling tired or winded, being physically active, and walking far or quickly. Participants' responses were combined into a score.

    That score can help researchers compare patterns between groups, but it compresses many different experiences. An improvement in an average score doesn't tell you which activity changed for every participant. One person might notice a difference on stairs; another might notice no change in that activity but report a different benefit or difficulty.

    Scores also depend on where a person starts. Someone who already reports little difficulty with an activity has less room to show improvement on that question than someone who reports substantial difficulty. Researchers need to consider the population and the measure when interpreting the result.

    What did the comparisons show?

    In STEP 1 and STEP 2, the analysis reported greater average improvement in the weight-related physical-function score with semaglutide than with placebo. For the general physical-function questionnaire, the semaglutide group showed greater average improvement in STEP 1, STEP 2, and STEP 4.

    STEP 3 was different: improvements on that general physical-function measure were similar in the semaglutide and placebo groups, and the difference was not statistically significant. Both groups in STEP 3 received intensive behavioral support. The study was not designed to prove why that particular questionnaire result differed from the other trials.

    “Not statistically significant” doesn't prove the treatments had exactly the same effect. It means the study did not establish a clear difference on that measure using its analysis. Equally, a significant group difference in another trial doesn't guarantee a noticeable change for every individual.

    What the results can't tell you

    Questionnaires rely on participants' reports and are influenced by what the questions cover. They don't measure every activity or every aspect of well-being. Participants may have different work demands, disabilities, pain, support, and access to movement opportunities. A trial average cannot capture all of those differences.

    Some participants did not complete every assessment, and the study's analysis had to account for missing information. The findings also apply to the treatments, populations, and follow-up periods studied—not automatically to every semaglutide formulation or other medication.

    Side effects and the burden of treatment matter, too. A useful conversation about functioning includes what has improved, what remains difficult, and what may have become harder.

    Define a goal that belongs to you

    If you're discussing weight care, you might tell your clinician: “I'd like to carry groceries with fewer breaks,” or “I want to feel comfortable at work through the afternoon.” Your goal could be about energy, pain, mobility, sleep, or something else entirely. It doesn't need to look like a trial questionnaire.

    Ask how you and your team can track that goal and what other support may help. Depending on your situation, that could include physical therapy, an accessible activity, nutrition support, pain care, or a review of symptoms and medicines. If a new activity causes pain or dizziness, stop and seek appropriate guidance.

    The STEP questionnaires remind us to ask patients how daily life feels. Their results are one part of the evidence; your own priorities and experience are another essential part of the conversation.